FindDrugs.org

Noom Review

Brand-level review · Last reviewed Sep 14, 2026

6.07/10

Operator-trust score

The brand-level factors every category shares — legitimacy, clinical oversight, transparency, privacy, policy, support — not price or per-treatment value.

How much separate evidence is behind this score

This score is made of 9 factors resting on 6 distinct pieces of evidence, because some factors were assessed from the same recorded signal:

  • Popularity & Momentum (82) · Access & Speed (72) · Transparency & Disclosure (50) · Clinical Oversight & Safety (66)“Noom bundles medication, clinical care and the behavioural programme into one GLP-1Rx subscription as described on its own page. The separate-layer billing structure previously described here came from a third-party revi…”

We publish this because a factor scored from evidence another factor also rests on is not independent of it. The score stands as computed; the methodology explains what that means for reading one.

No commitmentCash-payInsurance-billed

Our verdict

Noom is one of the most recognised weight-loss brands in the world, and its medication arm, Noom Med, adds a GLP-1 telehealth track on top of the psychology-based coaching that is its core competency. Its operator-trust score is 6.07 — the brand-level factors every category shares, not price or per-treatment value. Legitimacy is its genuine strength: Noom, Inc. has been BBB-accredited at an A+ rating since October 2021. Against that sit its policy record and its opacity — it settled a certified class action over automatic-renewal enrollment and cancellation practices, and it names neither a prescriber nor a dispensing pharmacy anywhere on its GLP-1 page.

Noom plans & reviews by category

Each category is scored separately. Read the full review where one exists — or check current pricing directly.

Weight Loss / GLP-1

5.83/10
Read the Weight Loss / GLP-1 reviewCheck price
  • Semaglutide · injection$279/mo
  • Semaglutide · injection$99/mo

Prices as of Sep 14, 2026 — verify current on the brand's site.

Key takeaways

  • Noom, Inc. is a large, established US company, BBB-accredited with an A+ rating since October 2021 — legitimacy is a genuine strength here.
  • It settled a certified class action over its automatic-renewal enrollment and cancellation practices: Nichols v. Noom Inc., No. 1:20-cv-03677 (S.D.N.Y.), terminated 2022-07-12 on a court-approved settlement that included enhanced auto-renewal disclosures.
  • It discloses the compounded-versus-approved distinction plainly on its own GLP-1 page but names no partner or dispensing pharmacy anywhere on it — sourcing disclosed in kind, not in identity.
  • Eligibility screening is documented: BMI thresholds of 27+ with a comorbidity or 30+, pre-prescription labs via Quest or Labcorp, and screening for the labelled contraindications.
  • It does not publish a titration schedule or state how much dose autonomy a patient has — not disclosed, rather than known to be poor.
  • Its BBB profile carries a substantial complaint volume concentrated on billing, cancellation and difficulty reaching support.
  • Behavioural coaching is its real differentiator, but customer-service responsiveness around billing and refunds, and the authenticity of coach interactions, are recurring pain points.

What is Noom?

Noom, Inc. is an established US health-and-wellness company best known for a behavioural, psychology-based weight-loss app. Its medication arm, Noom Med, connects members with US-licensed physicians and nurse practitioners who evaluate a health-history intake and order labs before prescribing a GLP-1. That medical programme is largely asynchronous and programme-mediated, and individual prescribers are not disclosed. Noom Med is available in 47 states, excluding Alabama, Louisiana and Mississippi, and the company has been BBB-accredited with an A+ rating since October 2021.

Is Noom legit?

Yes, with the caveat that the medication layer is the newest part of it. Noom, Inc. is a large, established US company that has been BBB-accredited at A+ since 2021, and its GLP-1 track uses US-licensed clinicians who order lab work before prescribing. What to weigh is that this track is a bolted-on addition to a coaching business, that the company settled a class action over auto-renewal enrollment and cancellation practices, and that it names no prescriber and no dispensing pharmacy.

  • Licensed & accredited: Noom, Inc. is BBB-accredited with an A+ rating (since Oct 2021) — a large, widely recognized U.S. company — BBB profile, Jul 2026.
  • Clinician model: U.S.-licensed physicians and NPs evaluate a health-history intake and order labs (A1C, kidney function) via Quest/Labcorp before prescribing, though oversight is largely asynchronous and prescribers are unnamed — Noom (noom.com), Jul 2026.
  • Medication & pharmacy: Compounded medication comes from an FDA-registered compounding facility and no specific dispensing pharmacy is named — HealthReviewNetwork, Jul 2026.
  • Watch-outs: Noom settled a class action over auto-renewal/subscription practices (the settlement amount rests on no record we retrieved) and drew an earlier BBB warning over billing complaints; the GLP-1 track is a newer addition — BBB profile / class-action settlement record, Jul 2026.

Treatment options

What Noom actually treats. Pricing lives in the plans table above and in each category review.

  • Weight loss (GLP-1)

    compounded semaglutide with the medication included, and branded GLP-1s prescribed with the drug purchased separately

Pros & cons

Pros

  • Established, widely recognized company with an enormous user base and strong brand momentum
  • Genuine behavioral/psychology coaching layer alongside the medication track
  • Documented eligibility screening: BMI thresholds, contraindication questionnaire, labs via Quest/Labcorp
  • Wide medication menu (compounded + branded) and availability in 47 states
  • BBB-accredited (A+) and a high-volume Trustpilot presence (~4.5, ~66k reviews)

Cons

  • Long, documented consumer-protection history: an auto-renewal/dark-pattern class-action settlement (amount unestablished) and a BBB warning after thousands of complaints
  • Notorious for hidden costs, billing surprises, and difficult cancellation; compounded plan billed quarterly with no mid-cycle refund
  • Layered/confusing pricing - coaching subscription and Noom Med fee are separate, and branded medication cost is on top
  • GLP-1 clinical operations are opaque: no named prescribers or named pharmacy disclosed
  • Quality-under-growth concerns (repetitive content) and a 2025 pivot to compounded microdosing

The bottom line

Noom suits people who want the behavioural programme first and the medication second, and who are comfortable with a programme-mediated clinical layer they cannot see into. Weigh that against layered pricing, an operation that names neither prescriber nor pharmacy, and a documented auto-renewal settlement alongside ongoing billing and cancellation complaints — and set a reminder to manage the subscription closely.

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 18, 2026Initial score6.07

    Noom's Operator Trust Score first recorded at 6.07 out of 10 — the earliest score in this log.

Review score changes

The timeline above is this brand's Operator Trust Score. Each review below is scored separately, and keeps its own history.

  • Weight Management / GLP-1 review— last changed Sep 14, 2026See changes

Work at Noom?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Completeness was not recorded for this score · 8 sources cited

Brand site

Regulatory

Reviews

Other

What we couldn't verify

  • Noom does not disclose the names of its prescribing clinicians for the GLP-1 track (opacity, scored low - not excluded).
  • The specific compounding/dispensing pharmacy (503A/503B) is not named to consumers (opacity, scored low).
  • Noom describes a clinician-managed titration approach on noom.com/med/glp-1rx/ ("What is the dosing schedule…" — a low starting dose increased over time) but publishes no dose-by-dose schedule. A previous pass recorded this as "no published titration protocol" and scored it as opacity; a live check on 2026-08-25 found the page answers that question, so the recorded non-disclosure was a fact about our reading. The subscore still reflects the earlier reading and has NOT been recomputed here.
  • Exact current core Noom coaching subscription price not re-verified this session (~$70/mo).
  • Whether a compounded microdose plan is billed $79/mo or $537/12wk is reported inconsistently.
  • Withdrawn — Noom's partner pharmacies. Noom's partner pharmacies are WITHDRAWN as a claim: noom.com/med/glp-1rx/ names no pharmacy (fetched 2026-08-10), and the third-party review site asserting the arrangement does not originate it. Noom does disclose on the same page that its compounded semaglutide is "produced in an FDA-registered facility but has not been reviewed by the FDA".
  • Withdrawn — Noom settlement amount (reported variously as $56m and "over $60m"). The Noom settlement amount (reported variously as $56m and "over $60m") is WITHDRAWN as a figure. It rested on a law-firm marketing blog; the settlement order itself was not retrieved. The docket (Nichols v. Noom Inc., 1:20-cv-03677, S.D.N.Y., terminated 2022-07-12) establishes that the case settled, which is the load-bearing fact.
  • Withdrawn — Bot coaches posing as humans. "Bot coaches posing as humans" is WITHDRAWN. It is an affirmative adverse claim about deceptive practice, sourced to a blog post on an unrelated nutrition app's domain, with no primary record. The BBB complaint pattern, cited separately, carries consumer dissatisfaction honestly and on the ReviewSource axis where it belongs.
  • Withdrawn — characterisation of Noom's titration model as a "gap". The characterisation of Noom's titration model as a "gap" is WITHDRAWN: the source was a diagnostics vendor's blog — neither the originator of the fact nor independent of the category — and Noom publishes no titration schedule of its own to check it against.
  • glp1-titration-autonomy: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn item was a diagnostics vendor's blog opinion about Noom's titration model. Ours to lose, and we checked exactly one Noom page for a titration schedule. Not established.
Last reviewed Sep 14, 2026View the ledger